CROI 2017 Program and Information

Program and Agenda

1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS Maud Mavigner 1 , Justin O’Neal 2 , Siddhartha Bhaumik 1 , Jakob Habib 1 , Cameron Robinson 1 , Maria Alvarado 3 , Xiaodong Zhang 3 , Jens Wrammert 1 , Mehul Suthar 2 , Ann Chahroudi 1 1 Emory Univ, Atlanta, GA, USA, 2 Emory Vaccine Center, Atlanta, GA, USA, 3 Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA 1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE- MODIFIEDmRNA VACCINATION Michael J. Hogan 1 , Norbert Pardi 1 , Rebecca S. Pelc 2 , Hanne Anderson 3 , Charles McGee 4 , Michael J. Hope 5 , Mark G. Lewis 3 , Theodore C. Pierson 2 , Barton F. Haynes 4 , DrewWeissman 1 1 Univ of Pennsylvania, Philadelphia, PA, USA, 2 NIAID, Bethesda, MD, USA, 3 Bioqual, Inc, Rockville, MD, USA, 4 Duke Univ, Durham, NC, USA, 5 Acuitas Therapeutics, Vancouver, BC, Canada Target Audience : This session is directed to clinicians and scientists who are interested in understanding how broadly neutralizing antibody responses in HIV-1 infection develop, how they may be harnessed for preventive vaccines, and exploited for HIV cure. Level of Knowledge : It is assumed that the participants are familiar with the basic principles of how antibodies function. Objectives: • Describe how broadly neutralizing antibodies are stimulated during infection and following vaccination • Describe the structural properties of broadly neutralizing antibodies and their interaction with the HIV Envelope • Describe the potential of exploiting broadly neutralizing antibodies for functional cure Conveners Nicole Doria-Rose , National Institutes of Health, Bethesda, MD, USA Gabriella Scarlatti , Global HIV Vaccine Enterprise, New York, NY, USA 142 NEUTRALIZING ANTIBODY DEVELOPMENT DURING HIV-1 INFECTION Penelope Moore , Univ of the Witwatersrand, Johannesburg, South Africa 143 IMMUNOGEN DESIGN TO INDUCE HIV NEUTRALIZING ANTIBODIES William R. Schief , Scripps Rsr Inst, La Jolla, CA, USA 4:00 4:30 Symposium S-8 PATHS INTERTWINED: BROADLY NEUTRALIZING ANTIBODIES AND THE HIV-1 ENVELOPE TRIMER Room 606-609 4:00 PM - 6:00 PM

Oral Sessions • Thursday

144 STRUCTURAL STUDIES OF HIV NEUTRALIZING ANTIBODIES Andrew B. Ward , Scripps Rsr Inst, La Jolla, CA, USA 145 CLINICAL STUDIESWITH BROADLY NEUTRALIZING ANTIBODIES Michel Nussenzweig , Rockefeller Univ, New York, NY, USA 5:00 5:30

CROI 2017 70